A small but carefully designed clinical trial has added meaningful weight to the idea that gut health and mood are biologically connected — with practical implications for millions of older Americans living with depression.
The trial, published June 17, 2026, in the Journal of the American Geriatrics Society (JAGS), enrolled 58 adults aged 60 and older with moderate depression. Participants were randomly assigned to receive either a daily probiotic supplement (containing Lactobacillus helveticus and Bifidobacterium longum) or a placebo for 12 weeks, while both groups continued their prescribed antidepressant treatment.
The result: older adults who added the probiotic experienced meaningfully greater reductions in both depressive and anxiety symptoms than those who received the placebo.
Why This Matters
Depression is common in older adults and difficult to treat. Standard antidepressants are effective in roughly half of patients — a success rate that leaves millions without adequate relief. In older adults specifically, antidepressant response rates are lower still, side effects are more pronounced, and polypharmacy (taking many medications simultaneously) adds complexity to treatment decisions.
A daily probiotic is inexpensive, widely available without a prescription, and has a well-established safety profile in healthy older adults. If it can augment the effect of antidepressants already being taken — with no significant drug interactions — that is a meaningful low-risk option worth discussing with a physician.
The qualification is equally important: this was a pilot trial of 58 people. It is preliminary evidence, not a treatment recommendation.
What We Know So Far
The PRODG trial (Efficacy of Adjunct PRObiotics in Moderate Unipolar Depression in Geriatric Patients) is described by its authors as the first randomized, double-blind, placebo-controlled trial specifically designed to test probiotic adjunct therapy in a geriatric depression population.
According to ScienceDaily and Nutrition Insight reporting on the study, participants received either Lactobacillus helveticus and Bifidobacterium longum (approximately 6 billion CFU daily) or a placebo. Both groups continued their standard antidepressant treatment throughout.
Both groups showed substantial overall improvements over the 12-week period — a pattern typical of depression trials, where placebo response is often significant. The probiotic group showed meaningfully greater benefit. Researchers also found elevated serum levels of BDNF (brain-derived neurotrophic factor) — a protein that supports neuron survival and growth — in the probiotic group, and measurable shifts in gut bacteria composition consistent with enhanced gut-brain axis signaling.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Study type: Randomized, double-blind, placebo-controlled pilot clinical trial (PRODG)
- Participants: 58 adults aged 60 and older with moderate depression
- Treatment: Lactobacillus helveticus + Bifidobacterium longum (~6 billion CFU daily) vs. placebo for 12 weeks, alongside standard antidepressant treatment
- Published in: Journal of the American Geriatrics Society, June 17, 2026
- What it found: Meaningfully greater reduction in depression and anxiety symptoms in the probiotic group; elevated BDNF levels; measurable shifts in gut bacteria composition
- What it did not find: Significant improvement in quality of life or cognitive performance (possibly due to small sample size)
- Key limitation: 58 participants is small. The trial was conducted in India; how well findings translate to other populations requires further study. A larger confirmatory trial is planned but not yet conducted.
- What readers should know: This is promising preliminary evidence for a low-risk, low-cost intervention. Discuss with a physician before adding any supplement to an existing treatment regimen.
Co-corresponding author Saibal Das, MBBS, MD, DM, PhD of the Indian Council of Medical Research stated: “The results of our study are novel, and we are now planning a follow-up, larger-scale clinical trial due to the encouraging findings.”
What Doctors and Experts Say
The gut-brain axis — the bidirectional communication network between the gastrointestinal microbiome and the central nervous system — has gained substantial scientific credibility over the past decade. Microbial diversity decreases with age, and communities shift toward pro-inflammatory configurations that may parallel the neuroinflammatory processes observed in geriatric depression.
Dr. Abhinaba Ghosh, physician and neuroscientist at Tata Medical Center, and lead author, said: “We found that adding specific strains of probiotics has the potential to enhance improvement in depression and anxiety. We did not see a change in the quality of life of the patients, probably because this is a pilot study and there weren’t enough patients. We plan to address this in a follow-up full-scale clinical trial.”
Psychiatrists reviewing the data have noted that the biological plausibility is sound, the safety profile is established, and the low cost makes the risk-benefit ratio favorable enough to be a reasonable discussion item between patients and their physicians.
Who Faces the Greatest Risk?
Older adults with depression who have not achieved adequate symptom relief with their current antidepressant regimen are the primary population for whom this discussion is most relevant. People who are not responding well to treatment, who want low-risk supplementary options, and who are otherwise healthy without contraindications to probiotic use are the most appropriate candidates for this conversation.
People who are immunocompromised — including those undergoing chemotherapy, taking immunosuppressants, or with HIV — should consult their physician before starting any probiotic, as probiotics carry a small risk of translocation (movement of bacteria into the bloodstream) in severely immunocompromised individuals.
What You Can Do Now
- If you are an older adult taking antidepressants and are not achieving adequate symptom relief, ask your physician whether adding a probiotic supplement is something worth trying as an adjunct to your current treatment.
- The specific strains used in the trial were Lactobacillus helveticus and Bifidobacterium longum. Products containing these strains are widely available at pharmacies without a prescription.
- Do not stop or change your antidepressant without discussing it with your physician first. The trial showed benefit from adding a probiotic alongside existing treatment — not from replacing it.
- If you are immunocompromised or have serious gastrointestinal conditions, consult your physician before starting any probiotic supplement.
- Monitor for the larger confirmatory trial, which the research team says is in planning.
Cost and Access: What Patients Should Know
Probiotic supplements are widely available at pharmacies and grocery stores without a prescription, typically costing $15 to $40 per month. They are not covered by most insurance plans but are accessible to most people without financial hardship. A physician’s recommendation is not required to purchase them, but discussing any supplement change with your prescribing physician is advisable to ensure there are no contraindications with existing medications.
What Happens Next
The research team has announced plans for a larger, full-scale confirmatory trial. No timeline has been publicly specified. Until that trial is completed, the PRODG results should be treated as promising preliminary evidence warranting further study — not as established treatment guidance. MedicalDaily will report on the confirmatory trial results when published.
The Bottom Line
A well-designed pilot trial has found that seniors with depression who added a daily probiotic to their antidepressant showed greater improvement than those on placebo, meaningfully, with biological markers to support the finding. The evidence is preliminary, the sample is small, and a larger trial is needed. But the safety profile is good, the cost is low, and the risk-benefit conversation with a physician is reasonable. If you are an older adult who is not getting adequate relief from antidepressants, this is worth asking your doctor about.
